Search

Your search keyword '"Hellriegel, Martin"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Hellriegel, Martin" Remove constraint Author: "Hellriegel, Martin"
35 results on '"Hellriegel, Martin"'

Search Results

1. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

2. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

3. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

4. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

5. Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study

7. Role of tumour-free margin distance for loco-regional control in vulvar cancer—a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study

9. Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study

10. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group

11. Pelvine Lymphonodektomie beim Vulvakarzinom - Wohl oder Übel?

13. Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?

14. Correlation of cone-beam breast-CT, digital breast tomosynthesis and full-field digital mammography with histopathology

15. p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE-translational study group.

17. Corrigendum to 'Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group'

19. Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study

21. Corrigendum to “Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group” [Eur J Cancer 49 (2013) 1905–1914]

22. The course of vulvar cancer: The utility of multistate models in the AGO-CaRE-1 study.

23. Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

24. Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study.

30. Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group

31. A genome-wide survey of RAS transformation targets

34. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

35. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.

Catalog

Books, media, physical & digital resources